UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...

HIV incidence in sub-Saharan Africa has declined substantially, according to both UNAIDS estimates and empirical data pulled ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Zúñiga believes that interventions that target LDHB or related metabolic pathways could be explored as a way to counteract ...

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...

SLIM LIVER was the first clinical trial to test semaglutide as a treatment for MASLD in people living with HIV. MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is a common and ...